Arch Biopartners Enrolling Volunteers in Phase 1 Trial of AB569, Therapy Candidate for Drug-resistant Bacterial Lung Infections
A Phase 1 clinical trial testing Arch Biopartners’ AB569 for the treatment of antibiotic-resistant bacterial infections is now enrolling healthy volunteers. The therapy candidate could be a new help for patients with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The trial will evaluate the…
